Publications

Found 8 results
Author Title [ Type(Desc)] Year
Filters: Author is DeMattos, Ronald B  [Clear All Filters]
Journal Article
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'dell MA, Taylor JW, Harmony JAK, Aronow BJ, Bales KR, Paul SM et al..  2004.  ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.. Neuron. 41(2):193-202.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.  2002.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.. Science. 295(5563):2264-7.
DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM.  2002.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 99(16):10843-8.
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC et al..  2009.  A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.. Ann Neurol. 66(1):48-54.
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C et al..  2011.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.. Sci Transl Med. 3(89):89ra57.
Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM et al..  2002.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.. Nat Neurosci. 5(5):452-7.
Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SDan, Jiang X-C et al..  2004.  A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.. J Neurochem. 88(3):623-34.
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, DeMattos RB.  2010.  Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.. Clin Neuropharmacol. 33(2):67-73.